Endpoints for clinical trials of sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 29, Issue 2, 2012, Pages 90-98

  Baughmann, Robert P ^a   Drent, M ^b   Culver, D A ^c   Grutiers, J C ^d   Handa, T ^e   Humbert, M ^f   Judson, M A ^g   Lower, E E ^a   Mana, J ^h   Pereira, C A ⁱ   Prasse, A ^j   Sulica, R ^k   Valyere, D ^l   Vucinic, V ^m   Wells, A U ⁿ  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g ALBANY MEDICAL CENTER   (United States)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^j UNIVERSITY OF FREIBURG   (Germany)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l AVICENNE HOSPITAL   (France)

^m CLINICAL CENTER OF SERBIA   (Serbia)

ⁿ ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Fatigue assessment scale; Forced vital capacity; Quality of life; Scadding stage; Short form 36

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; INFLIXIMAB; PLACEBO; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL OUTCOME SCORE; CLINICAL TRIAL (TOPIC); COGNITIVE FAILURE QUESTIONNAIRE; DISEASE CLASSIFICATION; FATIGUE; FATIGUE ASSESSMENT SCALE; FATIGUE SCALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY; GENOTYPE PHENOTYPE CORRELATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG SARCOIDOSIS; LUPUS PERNIO ACTIVITY AND SEVERITY INDEX; MEDICAL PHOTOGRAPHY; NEW YORK HEART ASSOCIATION CLASS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REPRODUCIBILITY; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SARCOIDOSIS; SARCOIDOSIS HEALTH QUESTIONNAIRE; SARCOIDOSIS THREE DIMENSIONAL ASSESSMENT INSTRUMENT; SCORING SYSTEM; SHORT FORM 36; SKIN BIOPSY; SKIN MANIFESTATION; THORAX RADIOGRAPHY; VALIDITY; WALKING; WORLD HEALTH ORGANIZATION QUALITY OF LIFE BRIEF SCALE;

CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX;

EID: 84872313151     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Israel HL. The treatment of sarcoidosis. Postgrad Med J 1970; 46:537-540.
2. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14(5):1117-1122.
3. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 1999; 116:424-431. (Pubitemid 29382128)
4. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846-851.
5. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8(5):470-476. (Pubitemid 34836955)
6. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43-48. (Pubitemid 38533813)
7. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174(7):795-802. (Pubitemid 44511661)
8. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60-66. (Pubitemid 30157757)
9. Baughman RP, Iannuzzi MC, Lower EE,et al. Use of fluticasone for acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:198-204.
10. Pietinalho A, Lindholm A, Haahtela T, Tukiainen P, Selroos O. Inhaled budesonide for treatment of pulmonary sarcoidosis. Results of a double-blind, placebo-controlled, multicentre study. Eur Respir J 1996; 9(2):suppl 23: 406s.
11. Rossman MD, Newman LS, Baughman RP, et al. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:201-208. (Pubitemid 47596315)
12. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287:1301-1307. (Pubitemid 34250485)
13. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003;(3):CD003536.
14. Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Gibson PG, Abramson M, Wood-Baker R, Volmick J, Hensley M, Costabel U, editors. Evidence-based respiratory medicine. Maiden: Blackwell Publishing Ltd.; 2005. 491-508.
15. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232. (Pubitemid 34754167)
16. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135(2):468-476.
17. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128(2):1062-67. (Pubitemid 41140552)
18. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:110-120.
19. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of Sarcoidosis-Associated Pulmonary Hypertension: A Two-Center Experience. Chest 2009; 135 (6): 1455-1461.
20. Judson MA. Ambrisentan for Sarcoidosis Associated Pulmonary Hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011;in press.
21. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22(3):235. (Pubitemid 41668362)
22. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133(5):1189-1195. (Pubitemid 351685525)
23. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22(2):147-153. (Pubitemid 41020022)
24. de Kleijn WP, de Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15(5):499-506.
25. Latsi PI, du Bois RM, Nicholson AG, et al. Fibroric idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168(5):531-537. (Pubitemid 37088594)
26. Collard HR, King TE, Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168(5):538-542. (Pubitemid 37088595)
27. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168(5):543-548. (Pubitemid 37088596)
28. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353(21):2229-2242. (Pubitemid 41697286)
29. Muers MF, Middleton WG, Gibson GJ, et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14(1):46-56. (Pubitemid 27170555)
30. Baughman RP, Shipley R, Desai S, et al. Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy: Comparison of Different Methods of Evaluation. Chest 2009; 136:526-535.
31. Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14(1):65-72. (Pubitemid 27170557)
32. Drent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003; 13(11):2462-2471. (Pubitemid 37407478)
33. Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med 2010; 16 Suppl 1:S1-9.:S1-S9.
34. Galie N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 2010; 16 Suppl 1:S11-9.:S11-S19.
35. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 Suppl 2:S8.:S8.
36. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130(5):1481-1488. (Pubitemid 44786743)
37. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27(3):329-334. (Pubitemid 351375107)
38. Judson MA, Kwon S., Highland KB, et al. The assessment of three health-related quality of life measurements assessed in ambrisentan trial for sarcoidosis-assocaited pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:S20.
39. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5(5):623-630. (Pubitemid 352031535)
40. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078-1085.
41. de Kleijn WP, Elfferich MD, De Vries J, et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26(2):92-97.
42. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21(1):S7-63.
43. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102(11):1636-1642.
44. Korenromp IH, Heijnen CJ, Vogels OJ, van den Bosch JM, Gratters JC. Characterization of chronic fatigue in sarcoidosis in clinical remission. Chest 2011; 140(2): 441-447.
45. De Vries J, Michielsen H, van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9(Pt 3):279-291. (Pubitemid 39277403)
46. Hinz A, Fleischer M, Brahler E, Wirtz H, Bosse-Henck A. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011; 33(5): 462-468.
47. de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105(9):1388-1395.
48. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexamethylphenidate for the treatment of fatigue following cancer chemotherapy: a randomized clinical trial. J Clin Oncol 2005; 23 (16S): 8000.
49. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Resp Crit Care Med 2003; 168:323-329. (Pubitemid 36969884)
50. Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23(1):51-57. (Pubitemid 44259209)
51. De Vries J, Lower EE, Drent M. Quality of life in sarcoidosis: assessment and management. Semin Respir Crit Care Med 2010; 31(4):485-493.
52. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38 (3): 628-634.
53. Baydur A, Alavy B, Nawathe A, Liu S, Louie S, Sharma OP. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 2011; 5(3):156-164.
54. Korenromp IH, Gratters JC, van den Bosch JM, Zanen P, Kavelaars A, Heijnen CJ. Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue. Brain Behav Immun 2011; 25(7): 1498-1502
55. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60(1):32-38. (Pubitemid 40101015)
56. Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. Sarcoidosis 1997; 14:61-64. (Pubitemid 27170556)
57. Verbraecken J, Hoitsma E, van der Grinten CP, Cobben NA, Wouters EF, Drent M. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21(2):137-146. (Pubitemid 38954754)
58. Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15(1):59-66. (Pubitemid 28174898)
59. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103(1):30-36. (Pubitemid 23027228)
60. Elfferich MD, Nelemans PJ, Ponds RW, de Vries J, Wijnen PA, Drent M. Everyday Cognitive Failure in Sarcoidosis: The Prevalence and the Effect of Anti-TNF-alpha Treatment. Respiration 2010; 80:212-219.
61. Baughman RP, Judson MA, Teirstein A, et al. Chronic facial sarcoidosis including lupus pernio : clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9(3):155-161. (Pubitemid 351572057)
62. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. The safety and efficacy of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2011;in press.
63. Stagaki E, Mountford WK, Lackland DT, Judson MA. The Treatment of Lupus Pernio: The Results of 116 Treatment Courses in 54 Patients. Chest 2008.
64. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002; 102(3):225-236. (Pubitemid 34259256)
65. Judson MA, Marchell RM, Masciarelli M, et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis. J Amer Acad Dermatology 2011;in press.
66. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager HJr, the ACCESS Research group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75-86. (Pubitemid 29164274)
67. Judson MA. A proposed solution to the clinical assessment of sarcoidosis: The sarcoidosis three-dimensional assessment instrument (STAI). Med Hypotheses 2007; 68(5):1080-1087. (Pubitemid 46274036)
68. Baughman RP, Nagai S, Baiter M, et al. Defining the clinical out come status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(1):56-64.
69. Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129(5):1234-1245.
70. Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Muller-Quemheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177(3):330-336. (Pubitemid 351198377)
71. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181(4):315-323.
72. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368(9537):804-813. (Pubitemid 44279058)
73. Rodrigues SC, Rocha NA, Lima MS, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(1):34-43.
74. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003; 167(9):1225-1231. (Pubitemid 36555094)
75. Kreider ME, Christie JD, Thompson B, et al. Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest 2005; 128(1):207-215. (Pubitemid 40994475)
76. Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med 2010; 31(4):380-389.